“Short-term I expect the impact to be minimal to Pharma, perhaps a financial hit to their stock. Depending on the burn rate of individual biotechs, the short term effect could be significant if investors are losing patience. Probably the biggest impact long term for both will be in human resources, but this will depend on what EU exit package is negotiated between Britain and the EU. Only time will tell what that is.”Peter Banks, Ph.D., Scientific Director, BioTek Instruments (US)